Navigation Links
Statement From Lilly on FDA Advisory Committee Recommendation Regarding Liprotamase New Drug Application for Treatment of Exocrine Pancreatic Insufficiency
Date:1/12/2011

INDIANAPOLIS, Jan. 12, 2011 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced the U.S. Food and Drug Administration (FDA) Gastrointestinal Drugs Advisory Committee voted today to recommend non-approval of liprotamase, a non-porcine pancreatic enzyme replacement therapy (PERT), currently under FDA review for the treatment of exocrine pancreatic insufficiency (EPI).

During the meeting, the committee had questions about the degree of efficacy of liprotamase and recommended that additional studies be conducted prior to considering approval of liprotamase for EPI.  

"We appreciate the feedback the committee has provided, and we will continue to work with the FDA to address the questions raised in the meeting as the agency moves toward a final decision on the application," said Eiry Roberts, M.D., Vice President, Autoimmune, Bone-Muscle-Joint, Liprotamase Product Development at Lilly. "We remain confident in the clinical trial data package submitted to the FDA in support of the liprotamase application."

The FDA is not required to follow the recommendation of its advisory committees.

About Liprotamase & Pancreatic Enzyme Replacement Therapy

Liprotamase is an oral, non-porcine, pancreatic enzyme replacement therapy (PERT) under FDA review for the treatment of exocrine pancreatic insufficiency associated with cystic fibrosis and pancreatectomy. PERT is a treatment involving the oral administration of pancreatic enzyme replacements, which include protease, amylase and lipase.

Patients with EPI cannot properly digest and absorb nutrients including fat, protein and carbohydrates. Causes of EPI include cystic fibrosis (a life-threatening genetic disorder), chronic pancreatitis and pancreatectomy (surgical removal of the pancreas).

Cystic fibrosis affects approximately 30,000 children and adults in the United States and
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Statement by KCP Chairman Dr. Edward Jones in Response to FDA Advisory Committee on Benefits and Risks of Erythropoietin-Stimulating Agents in Treatment of Kidney Patients
2. Statement From The National Conclave on HIV/AIDS Policy for Black Clergy
3. Statement by US Oncology on FDA Label on Erythropoiesis Stimulating Agents (ESAs)
4. AIDS Action Council Statement on World AIDS Day 2007: Leadership Needed for a National Strategy to Stop the AIDS Epidemic
5. Statement of Andrea Kavanagh, Director, Pure Salmon Campaign, on the Science Sea Lice Study
6. Statement from the American Diabetes Association Related to ACCORD Trial Announcement
7. Media Statement: MHA Keystone Center for Patient Safety & Quality OHRP Ruling
8. Statement from Eli Lilly and Company: Response to Connecticut Attorney General News Release
9. Ortho Biotech Statement on U.S. Food and Drug Administration Oncologic Drugs Advisory Committee Vote
10. Statement From the Lupus Foundation of America Regarding the Release of Top-Line Results From a Study of Rituxan for the Treatment of Lupus
11. VA Statement on Smoking Cessation Research Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... 2015 IRIDEX Corporation (NASDAQ: IRIX ) ... 2015 financial results after the market closes on ... release, the Company will host a conference call with ... on Thursday, August 6, 2015 to ... developments. Interested parties may access the live ...
(Date:7/30/2015)... PARK, N.J. , July 30, 2015  Unichem ... voluntarily recalling one lot of Hydrochlorothiazide tablets 25 mg ... been initiated as a precautionary measure due to the ... of the product. The risk associated ... Hydrochlorothiazide tablet is the increased probability of experiencing Clopidogrel,s ...
(Date:7/30/2015)... China , July 30, 2015 Tianyin ... a pharmaceutical company that specializes in the patented biopharmaceutical, ... pharmaceutical ingredients (API), provided updates regarding the notice it ... LLC (the "Exchange") indicating that the Company was below ... forth in Sections 134 and 1101 of the NYSE ...
Breaking Medicine Technology:IRIDEX Announces Second Quarter 2015 Conference Call and Release Date 2Unichem Pharmaceuticals (USA), Inc. Issues a Voluntary Nationwide Recall of Hydrochlorothiazide Tablets Due to the Potential Presence of Foreign Tablets 2TPI Provides Update Regarding Non-Compliance with NYSE MKT Continued Listing Requirements 2
... SEATTLE, Oct. 15 Omeros Corporation (Nasdaq: ... and commercializing products focused on inflammation and disorders of ... Demopulos, M.D., chairman and chief executive officer, will present ... on October 22, 2010 at 1:30 p.m. Eastern time ...
... Tolerated in Multiple Sclerosis Patients -- PARIS, October 15, 2010 ... ... if (typeof(lpUnit)==,undefined,) var lpUnit=,PRN,; --> ... function(data) { var s = ,; var first_result; // Results are keyed by longUrl, so we need to grab ...
Cached Medicine Technology:Teriflunomide Successfully Reduces Relapses and is Well Tolerated in Multiple Sclerosis Patients 2Teriflunomide Successfully Reduces Relapses and is Well Tolerated in Multiple Sclerosis Patients 3Teriflunomide Successfully Reduces Relapses and is Well Tolerated in Multiple Sclerosis Patients 4Teriflunomide Successfully Reduces Relapses and is Well Tolerated in Multiple Sclerosis Patients 5Teriflunomide Successfully Reduces Relapses and is Well Tolerated in Multiple Sclerosis Patients 6Teriflunomide Successfully Reduces Relapses and is Well Tolerated in Multiple Sclerosis Patients 7Teriflunomide Successfully Reduces Relapses and is Well Tolerated in Multiple Sclerosis Patients 8Teriflunomide Successfully Reduces Relapses and is Well Tolerated in Multiple Sclerosis Patients 9Teriflunomide Successfully Reduces Relapses and is Well Tolerated in Multiple Sclerosis Patients 10Teriflunomide Successfully Reduces Relapses and is Well Tolerated in Multiple Sclerosis Patients 11Teriflunomide Successfully Reduces Relapses and is Well Tolerated in Multiple Sclerosis Patients 12
(Date:7/31/2015)... ... July 31, 2015 , ... Last week, the Mesothelioma ... store can be accessed by visiting http://www.curemeso.org/store . , “Our new store ... best part: whenever a product is purchased, the Meso Foundation receives a $5.00 ...
(Date:7/31/2015)... (PRWEB) , ... July 31, 2015 , ... There’s no ... possible, even when it comes time to cook the next meal, making July the ... July by practicing best grilling tips and recipes. , Make the next cookout different ...
(Date:7/31/2015)... CA (PRWEB) , ... July 31, 2015 , ... Coco ... the athletes, judges, media, and VIPs at the 2015 Vans US Open of Surfing, ... coconut water that can claim “no added sugar” on the market, is a natural ...
(Date:7/31/2015)... ... July 31, 2015 , ... According to the article published July 27 ... Pasadena courthouse was contained and extinguished by the city’s fire department before it caused major ... at the time of the fire, and it was a fire alarm system that tipped ...
(Date:7/31/2015)... York (PRWEB) , ... July ... ... attorney Jason T. Brown’s live lecture on pharmaceutical negligence is now available ... 2015 was well received with a 94% approval rating from the nationwide ...
Breaking Medicine News(10 mins):Health News:Mesothelioma Organization Launches New Store 2Health News:Mesothelioma Organization Launches New Store 3Health News:King Kullen Honors National Hot Dog and Blueberry Month 2Health News:King Kullen Honors National Hot Dog and Blueberry Month 3Health News:Coco Libre Brings Eco-conscious Hydration to Vans US Open of Surfing 2Health News:Article on Recent Pasadena Courtroom Fire Highlights the Effectiveness of Fire Alarm Systems, Says Fire Protection Group Inc 2Health News:Article on Recent Pasadena Courtroom Fire Highlights the Effectiveness of Fire Alarm Systems, Says Fire Protection Group Inc 3Health News:Re-Broadcast of Nationally Renowned Trial Attorney Jason T. Brown's Lecture on Pharmaceutical Negligence Now Available 2
... the FDA could be one of the most significant advances in ... say doctors involved in the research., ,Diabetes is a disease ... body (type 1 diabetes) or the body does not effectively use ... another hormone -- amylin -- to aid in the treatment of ...
... survey is a worldwide investigation of sociocultural and political ... network of social scientists. It includes questions about how ... their lives. ,It showed that average happiness has ... War II, although incomes have risen. ,The analysis ...
... death in many people, but previous research has not looked ... study focuses on depression in elderly people living in the ... ,The study, involved 250 participants in a community health program. ... of depression and then did so again at 18 months. ...
... care unit patients who receive a preventative round of antibiotics ... more likely to survive their ICU stay. // ... between ICU patients who were given antibiotics and those who ... antibiotics to kill harmful bacteria in the mouth, stomach, and ...
... be at risk for experiencing dangerous falls. ,Researchers studied more ... asked if they // had fallen in the last 12 months, ... medical attention for the falls. ,They also brought all ... history report. ,Results of the study show nearly three ...
... receives for breast cancer be putting her at higher ... ,Studies finds women who underwent simple mastectomy and radiotherapy ... had a radical mastectomy and no radiotherapy to later ... cancer rates were noted among a group of women ...
Cached Medicine News:Health News:ICU Survival can be improved by Antibiotic use 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: